Successful delivery of a bispecific antibody therapeutic to patients necessitates a manufacturing strategy that can accommodate the unique size, structure, and complexity of these molecules to ensure quality. We can perform manufacturability assessments to help clients choose the most suitable candidate for cell line development (CLD) and de-risk the development process. Read our full article by Dr. Fay Saunders, Director of Mammalian Cell Culture, Process Development to find out more! https://lnkd.in/eZYr8wiz
FUJIFILM Diosynth Biotechnologies
Biotechnology Research
Partners for Life, Advancing Tomorrow's Medicines
About us
For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.
- Website
-
http://www.fujifilmdiosynth.com
External link for FUJIFILM Diosynth Biotechnologies
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Billingham
- Type
- Public Company
- Founded
- 2011
- Specialties
- Biologics Process Development and Biologics cGMP Manufacturing
Locations
Employees at FUJIFILM Diosynth Biotechnologies
Updates
-
This week our team in Holly Springs celebrated the groundbreaking of the $1.2B expansion at our Holly Springs, North Carolina site! This expansion is a critical component of our Partners for Life 2030 Strategy - representing a significant increase of our commercial capacity in the coming years. By leveraging our KojoX principle of modularity, we believe we will increase our speed to go-live through replicating facility design. We are very proud of how our Holly Springs site continues to transform the industry and support bringing life impacting medicines to our clients' patients! You can read more here: https://lnkd.in/ewVmJzJv #Pharma #Biotech #Biotechnologies #Healthcare
-
-
A leading CDMO should deliver tangible solutions to industry challenges. At FUJIFILM Diosynth Biotechnologies, we're pioneering a future without limitations, ensuring faster and more effective delivery of life-changing medicines for patients worldwide. Discover how our latest work in continuous electroporation and producer cell lines is driving this vision forward in our latest article. https://lnkd.in/e6GWfbdV
-
Our June 2024 newsletter is here! Check out the latest happenings at FUJIFILM Diosynth Biotechnologies 🔬
FUJIFILM Diosynth Biotechnologies - June 2024
FUJIFILM Diosynth Biotechnologies on LinkedIn
-
We are proud to continue our partnership with Jacobs as together, we work towards the completion of one of the largest, end-to-end cell culture contract manufacturing facilities in North America. Read more below.
This just in 🔔 #OurJacobs will deliver a $1.2B expansion of FUJIFILM Diosynth Biotechnologies’ (FDB) end-to-end, large-scale cell culture contract manufacturing facility in Holly Springs, North Carolina! We will continue to serve as delivery partner providing engineering, procurement and construction management services for this program. The facility—poised to be one of the largest cell culture contract manufacturing facilities in North America—will increase FDB’s manufacturing capacity for life-impacting novel biologics therapies and medicines for patients across the globe. “This expansion of the project at Holly Springs is testament to the relationship of trust and accountability Jacobs and FUJIFILM Diosynth Biotechnologies have built,” said Jacobs’ Senior Vice President Koti Vadlamudi. “Together we’ll continue to leverage digital innovation and modular design so that medicines and therapies are delivered with quality, flexibility, speed and consistency—now at an even larger scale." Follow the link below to read the full press release and learn more about the expansion ⬇️ http://jcob.co/pk5c50SraIf #BeyondExcellence #BoldlyMovingForward #LifeSciences #manufacturing
-
-
Right now, our site in Hillerød is buzzing with activity. We're pushing into new technological territories and expanding our expertise in many different areas. Soon the addition of eight 20,000L bioreactors will make our facility the biggest end-to-end CDMO in Europe. If you're looking to make a tangible impact and grow your career, FUJIFILM Diosynth Biotechnologies in Hillerød is the place to be. Check out some of our opportunities here: https://lnkd.in/gyHaw4Zd #CDMO #Engineering #ProcessScience #Quality #Biotechnologies #CareerGrowth #Opportunities
-
Exciting Times at ESACT 2024 in Edinburgh! 👩🔬 Today, 🔬 Amy McMann presents on reducing cost-of-goods while enhancing product quality in our platform upstream process. Jun 24, 7:30-9:00 PM at Poster 374 ⚗️ John Raven shares insights on intensifying upstream bioprocesses. Jun 24, 2:15-3:45 PM at Poster 361 Plus, our PhD students from the Centre of Excellence in Bioprocessing will showcase groundbreaking work: 🧬 Rebecca Sizer, University of York, “Guardians of Expression: Preventing Transgene Silencing.” 2:30-4:00 PM, Poster 16 🧪 Sienna Butterfield, University of York, “Epigenetic Boost: Enhancing CHO Cells with CRISPR-Targeted Demethylation.” 7:30-8:00 PM, Poster 17 🧫 Alex Arrese-Igor Royuela, University of Edinburgh, “Engineering a lactate sensing and controlling system in CHO cells.” 7:30-9:00 PM, Poster 59 Join our experts and learn how we're pushing the boundaries of bioprocessing. See you there! 👋
-
-
Join us at ESACT 2024 in Edinburgh! 👩🔬 Monday the 24th: 🔬 Amy McMann presents on reducing cost-of-goods while enhancing product quality in our platform upstream process. Jun 24, 7:30-9:00 PM at Poster 374 ⚗️ John Raven shares insights on intensifying upstream bioprocesses. Jun 24, 2:15-3:45 PM at Poster 361 🧬 Rebecca Sizer, University of York, “Guardians of Expression: Preventing Transgene Silencing.” 2:30-4:00 PM, Poster 16 🧪 Sienna Butterfield, University of York, “Epigenetic Boost: Enhancing CHO Cells with CRISPR-Targeted Demethylation.” 7:30-8:00 PM, Poster 17 🧫 Alex Arrese-Igor Royuela, University of Edinburgh, “Engineering a lactate sensing and controlling system in CHO cells.” 7:30-9:00 PM, Poster 59 Tuesday the 25th: 🔬 Devika Kalsi will discuss our innovative toolbox approach for bispecific antibody cell line and process development. 2:30 PM - 4:00 PM at Poster 48 Join our experts and learn how we're transforming the industry. See you there! 👋
-
-
On June 13 we were honored to host 79 guests from 33 pharmaceutical companies at our site in Hillerød, Denmark, where we focused on exploring ways to achieve successful outcomes in drug product manufacturing. Our guests gained valuable insights into drug product and finished goods processes and best practices from subject matter experts at both FUJIFILM Diosynth Biotechnologies and SCHOTT Pharma. They also enjoyed the opportunity to network with fellow industry experts and to take a tour of our facility, featuring our state-of-the-art filling line. Thank you all for joining us and for contributing your insights. You can learn more about our drug product manufacturing services here: https://ow.ly/fpKU50SmlZK
-